Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Pustkovec

5 clinical trials in Pustkovec, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Pustkovec at a glance
5
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

5 trials in Pustkovec

Open in trial search
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting
Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Atrial fibrillation+2

Not recruiting
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Other cities in Czechia

The busiest research cities in the country

All 158 cities in Czechia

Clinical research in Pustkovec

What the registry says about research in the country

01 Cardiovascular Disease Management

Clinical research focusing on lipoprotein(a) reduction using novel therapeutic approaches for patients with established cardiovascular disease. The trials aim to evaluate new treatments for reducing major cardiovascular events.

  • Cardiovascular Death Prevention
  • Non-fatal Stroke Management
  • Urgent Coronary Care

Advanced studies are exploring innovative approaches to improve outcomes in high-risk cardiac patients.

02 Stroke Prevention Research

Innovative investigations comparing asundexian with established treatments for preventing stroke in patients with atrial fibrillation. These studies focus on developing safer and more effective anticoagulation strategies.

  • Atrial Fibrillation Management
  • Systemic Embolism Prevention
  • Bleeding Risk Assessment

Research aims to enhance stroke prevention while minimizing bleeding complications.

03 Preventive Cardiology

Groundbreaking research evaluating inclisiran for primary prevention of atherosclerotic cardiovascular disease. The studies target high-risk patients to prevent major adverse cardiovascular events.

  • Primary ASCVD Prevention
  • Cardiovascular Risk Reduction
  • Coronary Event Prevention

These trials represent significant advances in preventive cardiovascular medicine.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.